| CAS NO: | 81624-55-7 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 25mg | 电议 |
| 100mg | 电议 |
| Cas No. | 81624-55-7 |
| 别名 | N1,N1,N2,N2-四[(6-甲基-1H-苯并咪唑-2-基)甲基]-1,2-乙二胺 |
| 化学名 | N1,N1,N2,N2-tetrakis((6-methyl-1H-benzo[d]imidazol-2-yl)methyl)ethane-1,2-diamine |
| Canonical SMILES | CC1=CC=C2N=C(CN(CC3=NC4=CC=C(C)C=C4N3)CCN(CC5=NC6=CC=C(C)C=C6N5)CC7=NC8=CC=C(C)C=C8N7)NC2=C1 |
| 分子式 | C38H40N10 |
| 分子量 | 636.79 |
| 溶解度 | ≥ 63.7mg/mL in DMSO |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IC50: 1.7-4.0 μM for tested cancer cell lines NSC348884 is a nucleophosmin inhibitor. Nucleophosmin is identified as a multifunctional nucleolar phosphoprotein, which is dysregulated in human malignancies resulting in anti-apoptosis and differentiation inhibition. In vitro: NSC348884, which was identified as a putative nucleophosmin small molecular inhibitor, was found to be able to disrupt a hydrophobic pocket that was required for oligomerization, and NSC348884 could also inhibit the cell proliferation in distinct cancer cell lines and disrupt nucleophosmin oligomer formation. Moreover, the treatment of several cancer cell types with NSC348884 could dose-dependently upregulate p53 and also induce apoptosis that correlated with H2AX phosphorylation, poly(ADP-ribose) polymerase cleavage as well as Annexin V. Furthermore, NSC348884 could also synergize doxorubicin cytotoxicity on the viability of cancer cells [1]. In vivo: Previous study showed that the in-vivo intravasation and invasion could be significantly inhibited after the injection of NSC348884 into the tumor-bearing mice. In addition, there was no significant difference in overall cell death that was observed by histology in the treated tumors with the 4-hour brief treatments, indicating that the inhibition seen was specific to migration [2]. Clinical trial: Up to now, NSC348884 is still in the preclinical development stage. References: |
m.cnreagent.com